SG11202107396RA - Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers - Google Patents

Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Info

Publication number
SG11202107396RA
SG11202107396RA SG11202107396RA SG11202107396RA SG11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA
Authority
SG
Singapore
Prior art keywords
antibodies
solid tumor
advanced stage
stage solid
tumor cancers
Prior art date
Application number
SG11202107396RA
Other languages
English (en)
Inventor
Serena Masciari
Semra Yoruk
Karl Hsu
Nicolas Acquavella
Marie Bernardo
Robert Jabulowsky
Ugur Sahin
Friederike Gieseke
Trnkova Zuzana Jirakova
Timothy R Wagenaar
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202107396RA publication Critical patent/SG11202107396RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202107396RA 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers SG11202107396RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962794896P 2019-01-21 2019-01-21
US201962926379P 2019-10-25 2019-10-25
EP19306471 2019-11-14
PCT/US2020/014039 WO2020154189A1 (en) 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Publications (1)

Publication Number Publication Date
SG11202107396RA true SG11202107396RA (en) 2021-08-30

Family

ID=69582159

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107396RA SG11202107396RA (en) 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Country Status (13)

Country Link
US (1) US20220288199A1 (zh)
EP (1) EP3914355A1 (zh)
JP (1) JP2022518236A (zh)
KR (1) KR20210118870A (zh)
CN (1) CN113507963A (zh)
AU (1) AU2020210614A1 (zh)
BR (1) BR112021013965A2 (zh)
CA (1) CA3126110A1 (zh)
IL (1) IL284645A (zh)
MX (1) MX2021008605A (zh)
SG (1) SG11202107396RA (zh)
TW (1) TW202043274A (zh)
WO (1) WO2020154189A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017743A2 (pt) 2017-02-28 2020-04-07 Sanofi Sa rna terapêutico
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
KR20210119451A (ko) * 2019-01-21 2021-10-05 사노피 진행성 단계의 고형 종양 암에 대한 치료용 rna
US11932692B2 (en) 2020-09-03 2024-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a PD-1 inhibitor
AU2021372660A1 (en) * 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
IL302321A (en) * 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
CA3220882A1 (en) * 2021-07-02 2023-01-05 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
RU2723050C2 (ru) 2013-05-02 2020-06-08 Анаптисбайо, Инк. Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
GEP20227438B (en) 2015-07-30 2022-11-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
SG10201913631TA (en) * 2016-08-19 2020-03-30 Curevac Ag Rna for cancer therapy
BR112019017743A2 (pt) * 2017-02-28 2020-04-07 Sanofi Sa rna terapêutico

Also Published As

Publication number Publication date
AU2020210614A1 (en) 2021-08-26
CN113507963A (zh) 2021-10-15
JP2022518236A (ja) 2022-03-14
TW202043274A (zh) 2020-12-01
MX2021008605A (es) 2021-10-26
WO2020154189A1 (en) 2020-07-30
BR112021013965A2 (pt) 2021-09-21
CA3126110A1 (en) 2020-07-30
EP3914355A1 (en) 2021-12-01
KR20210118870A (ko) 2021-10-01
IL284645A (en) 2021-08-31
US20220288199A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
IL284645A (en) Therapeutic RNA and Anti PD1 antibodies for the treatment of solid cancer tumors in advanced stages
EP3891294A4 (en) METHODS OF TREATMENT FOR CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER
EP3999548A4 (en) CLAUDIN18 ANTIBODIES AND METHODS OF TREATMENT OF CANCER
IL276446A (en) Methods for the selection and design of safer and more effective antibodies against CTLA-4 for cancer treatment
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
HUE054571T2 (hu) Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
IL277861A (en) Axl-specific antibodies for cancer treatment
ZA202106392B (en) Therapeutic rna for prostate cancer
IL288086A (en) Methods and materials for cancer treatment
EP3775167A4 (en) METHODS OF TREATING CANCER USING TUMOR ANTIGEN SPECIFIC T LYMPHOCYTES
IL287554A (en) Rana is therapeutic for ovarian cancer
EP3713576A4 (en) CANCER TREATMENT METHODS
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
SG11202109514VA (en) Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
IL289335A (en) New cancer antigens and methods
IL289334A (en) New cancer antigens and methods
IL289205A (en) New cancer antigens and methods
IL289200A (en) New cancer antigens and methods
EP4072580A4 (en) PERSONALIZED TUMOR VACCINE AND ITS USE FOR CANCER IMMUNOTHERAPY
IL284646A (en) Therapeutic RNA for the treatment of solid cancer tumors in advanced stages
EP3691694A4 (en) MONOCLONAL DNA ANTIBODIES AGAINST CTLA-4 FOR TREATMENT AND PREVENTION OF CANCER
EP4081644A4 (en) METHOD AND MEANS FOR TREATING SOLID TUMOR DISEASES
EP3947472A4 (en) THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
EP4077677A4 (en) RNA NANOPARTICLE FOR THE TREATMENT OF LIVER CANCER
EP4058478A4 (en) USE OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY